Retatrutide vs Tirzepatide vs Semaglutide | Peptide Intel Hub

Semaglutide is a single-receptor GLP-1 agonist with no meaningful GIP or glucagon receptor activity. It is the cleanest published reference compound for isolating GLP-1 signalling in metabolic research.

Tirzepatide is a dual GLP-1 / GIP agonist — a single 39-amino-acid peptide engineered to activate both incretin axes simultaneously. The addition of GIP agonism produces a stronger composite metabolic signal than GLP-1 activation alone in the published preclinical and clinical literature.

Retatrutide is a balanced triple GLP-1 / GIP / glucagon agonist. The glucagon receptor arm is the headline distinction from tirzepatide — in published preclinical and phase 2 clinical research, triple-receptor activation has been associated with stronger hepatic-lipid oxidation and resting-energy-expenditure signals than either dual-incretin or single-GLP-1 activation.

Semaglutide: GLP-1 selective. Receptor occupancy and potency profiles make it the published reference for single-axis GLP-1 work and the natural GLP-1-only arm in dual or triple comparator panels.

Tirzepatide: balanced GLP-1 / GIP agonism with engineering that favours sustained GIP receptor occupancy alongside GLP-1 signalling. Receptor-bias literature continues to characterise the precise downstream signalling differences vs semaglutide.

Retatrutide: balanced GLP-1 / GIP / glucagon agonism, with the glucagon arm contributing the hepatic-lipid and energy-expenditure signal that distinguishes the compound from tirzepatide. Receptor-balance literature is still maturing.

Semaglutide is supported by the SUSTAIN (type 2 diabetes) and STEP (obesity) trial families, plus the SELECT cardiovascular-outcomes trial — the deepest published clinical-research dataset of the three compounds and the basis for most translational comparator work.

Tirzepatide is supported by the SURPASS (type 2 diabetes) and SURMOUNT (obesity) trial families, with SURMOUNT-MMO running for cardiovascular and all-cause-mortality endpoints. The SURPASS-2 head-to-head against semaglutide is the most cited direct dual-vs-single comparison in the public literature.

Retatrutide is supported by the TRIUMPH phase 2 / phase 3 trial programme, with TRIUMPH-1 (obesity), TRIUMPH-2 (type 2 diabetes with overweight), TRIUMPH-3 (cardiovascular) and TRIUMPH-4 (knee osteoarthritis with obesity) defining the published phase 2 data and the active phase 3 programme. The phase 2 readouts are the basis for the current research interest in the compound.

Semaglutide carries a C18 fatty diacid modification that supports a multi-day research half-life — typical reported half-life is approximately 165 hours (around 7 days), suitable for weekly-cadence research protocols. Stable to DPP-4 degradation.

Tirzepatide carries a C20 fatty diacid modification with a comparable acylation-driven albumin-binding profile — typical reported half-life is approximately 120 hours (around 5 days), supporting weekly research cadence with a slightly shorter exposure tail than semaglutide.

Retatrutide carries a fatty-acid modification supporting an extended half-life in a similar range to tirzepatide — reported half-life is approximately 6 days, also supporting weekly research cadence. Pharmacokinetic comparisons in research models typically use matched weekly dosing across all three compounds.

Semaglutide is chosen when the protocol requires a clean GLP-1-only arm, when re-using the extensive published clinical literature is part of the project design, or when a comparator study explicitly needs all three receptor-class arms. It is the reference single-axis GLP-1 compound.

Tirzepatide is chosen when the protocol requires dual GLP-1 / GIP signalling without glucagon receptor activation — typically energy-expenditure, hepatic-lipid or composite-metabolic models where the GIP arm is expected to amplify the GLP-1 signal. It remains the dual-agonist reference compound.

Retatrutide is chosen when the protocol requires the additional hepatic-lipid and energy-expenditure signal driven by the glucagon arm, or when a three-arm comparator study explicitly needs single / dual / triple receptor agonism in matched arms under a single analytical specification window.

Semaglutide, tirzepatide and retatrutide should only be sourced from suppliers that use independent third-party verification — Janoshik Analytical is the default verifier, with orthogonal independent laboratories used when batch chemistry calls for confirmation by a second method. Minimum release specification is ≥99.0% HPLC main-peak purity with matching mass-spectrometry molecular weight and water content within the published specification for each compound.

Batch COAs for all three compounds should be published by the supplier so a researcher can audit the analytical detail. The /trust/how-to-read-a-coa reference walks through every field on a modern COA.

All three compounds ship lyophilised under nitrogen. Hold the unopened vial at 2–8 °C; freeze at −20 °C for long-term storage. Reconstitution with bacteriostatic water (0.9% benzyl alcohol) supports a two-month (60-day) in-use stability window under refrigeration for semaglutide, tirzepatide and retatrutide alike.

Aliquot before any freeze. The single most common cause of measurable potency loss in research peptides is repeat freeze-thaw cycling — all three compounds benefit from single-thaw aliquot workflows. Vortex gently, never shake aggressively, and keep reconstituted vials away from direct light. The /research/compound-storage-guide reference covers the per-compound stability windows in detail.

Single (semaglutide): translational research re-using the GLP-1 clinical literature, single-axis receptor-selectivity work, the GLP-1-only arm in dual- or triple-comparator panels.

Dual (tirzepatide): protocols requiring GLP-1 / GIP synergy without glucagon receptor activation — energy-expenditure, hepatic-lipid and composite-metabolic models where the GIP arm amplifies GLP-1 signalling.

Triple (retatrutide): protocols where the glucagon arm is part of the experimental design — hepatic-lipid oxidation, resting-energy-expenditure and composite-metabolic models where triple-receptor activation is the headline pharmacological question.

For three-arm comparator studies, reputable suppliers can often reserve matched-batch inventory of semaglutide, tirzepatide and retatrutide against a project timeline so the experimental panel is sourced under a single analytical specification window.

Retatrutide is characterized as a novel triple agonist, activating the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide 1 (GLP-1), and glucagon receptors (PMID 37366315, PMID 38858523, PMID 41090431, PMID 37385280, PMID 40609566, PMID 40291085, PMID 40563436). This unique molecular structure is designed to enable potent activation of these three receptors (PMID 40563436). The development of such multi-agonist molecules represents a progression from earlier GLP-1 receptor agonists and dual agonists like tirzepatide (PMID 38843460, PMID 40685589). Animal studies have indicated retatrutide's capability to delay gastric emptying, reduce food intake, and promote weight loss, showing superior efficacy compared to other incretin-based therapies in these models (PMID 40563436).

In the context of other GLP-1-based medicines, tirzepatide is noted as a GIP-GLP-1 receptor coagonist, while other investigational molecules like maritide block the GIP and activate the GLP-1 receptor (PMID 38843460). Retatrutide, in contrast, enables simultaneous activation of the glucagon and GLP-1 receptors, in addition to GIP (PMID 38843460). This triple agonism is being investigated for its potential in treating obesity and related complications, such as obstructive sleep apnea (OSA) and knee osteoarthritis (OA), through a novel basket trial design that simultaneously evaluates retatrutide across these multiple adiposity-related disease states (PMID 41090431).

The comprehensive TRIUMPH clinical development program is evaluating the safety and efficacy of retatrutide across various metabolic conditions (PMID 41090431, PMID 40563436). This program consists of four Phase 3, multicenter, randomized, double-blind studies that compare weekly subcutaneous retatrutide to placebo, alongside a healthy diet and physical activity, involving over 5800 participants (PMID 41090431). These trials include weight management studies, with OSA and OA protocols nested within them, and a separate trial for a population with cardiovascular disease (PMID 41090431). The primary endpoints vary by condition, including percent change in body weight for weight management, change in Apnea-Hypopnea Index for OSA, and changes in the Western Ontario and McMaster Universities Osteoarthritis Index pain subscale score for knee OA (PMID 41090431).

In phase 2 human trials, retatrutide demonstrated substantial body weight reductions in adults with obesity (PMID 37366315, PMID 38858523, PMID 40291085, PMID 39318607). A 48-week phase 2, double-blind, randomized, placebo-controlled trial involving 338 adults with a BMI of 30 or higher, or a BMI of 27 to less than 30 with at least one weight-related condition, showed dose-dependent weight loss (PMID 37366315). At 24 weeks, the least-squares mean percentage change in body weight in the retatrutide groups ranged from -7.2% (1-mg group) to -17.5% (12-mg group), compared with -1.6% in the placebo group (PMID 37366315). By 48 weeks, these reductions were -8.7% (1-mg group) to -24.2% (12-mg group), versus -2.1% for placebo (PMID 37366315).

Further analysis at 48 weeks revealed that a weight reduction of 5% or more was achieved by 92% of participants receiving 4 mg of retatrutide, 100% of those receiving 8 mg, and 100% of those receiving 12 mg, compared to 27% in the placebo group (PMID 37366315). Similarly, a reduction of 15% or more was seen in 60%, 75%, and 83% of participants in the 4 mg, 8 mg, and 12 mg retatrutide groups, respectively, versus 2% in the placebo group (PMID 37366315). A systematic review and meta-analysis of randomized controlled trials corroborated these findings, reporting a significant body weight reduction (mean difference [MD]: -14.33%) in obese patients treated with retatrutide (PMID 40291085). Another meta-analysis found that once-weekly subcutaneous retatrutide significantly reduced body weight (WMD -10.66 kg) compared to placebo (PMID 39318607).

Beyond overall weight loss, a substudy of a phase 2 trial in people with type 2 diabetes investigated the effects of retatrutide on body composition (PMID 40609566). The primary substudy endpoint was the percent change in total fat mass from baseline to week 36, measured by dual-energy X-ray absorptiometry (DXA) (PMID 40609566). Although specific percentage reductions in fat mass are not detailed in the abstract, the study aimed to assess this aspect, building on retatrutide's demonstrated glucose and bodyweight reductions in this population (PMID 40609566). Clinical trials have also shown that retatrutide led to reductions in BMI (MD: -5.38) and waist circumference (MD: -10.51 cm) (PMID 40291085, PMID 39318607).

Retatrutide has shown promising results in improving various metabolic markers in human studies. In a substudy of a phase 2 obesity trial, retatrutide significantly reduced liver fat (LF) in participants with metabolic dysfunction-associated steatotic liver disease and at least 10% LF (PMID 38858523). At 24 weeks, the mean relative change from baseline in LF ranged from -42.9% (1 mg) to -82.4% (12 mg), compared to +0.3% in the placebo group (all P < 0.001 versus placebo) (PMID 38858523). Furthermore, normal LF (<5%) was achieved by 27% to 86% of participants in the retatrutide groups, versus 0% in the placebo group (PMID 38858523). These LF reductions were significantly correlated with changes in body weight, abdominal fat, and metabolic measures indicating improved insulin sensitivity and lipid metabolism (PMID 38858523).

In patients with type 2 diabetes, retatrutide demonstrated clinically meaningful glucose-lowering efficacy (PMID 37385280, PMID 40609566). A phase 2 trial in this population showed that retatrutide significantly reduced hemoglobin A1c (HbA1c) (MD: -0.91%) and fasting plasma glucose (MD: -23.51 mg/dL) (PMID 40291085). Similar to retatrutide, tirzepatide, a dual GIP-GLP-1 receptor agonist, has also shown significant improvements in glycemic control and body weight in adults with type 2 diabetes (PMID 34170647, PMID 38388874). In an open-label, 40-week phase 3 trial, tirzepatide at all tested doses (5 mg, 10 mg, 15 mg) was noninferior and superior to semaglutide (1 mg) in reducing glycated hemoglobin levels (PMID 34170647). The estimated mean change from baseline in HbA1c with tirzepatide ranged from -2.01 to -2.30 percentage points, compared to -1.86 percentage points with semaglutide (PMID 34170647).

Regarding cardiovascular outcomes, real-world evidence from an insured US population with overweight/obesity and established atherosclerotic cardiovascular disease (ASCVD) without diabetes compared semaglutide and tirzepatide (PMID 41491349). In this observational cohort study, semaglutide was associated with statistically significant reductions of 29% in the risk of revised 3-point MACE (rMACE-3: MI, stroke, all-cause mortality) and 22% in the risk of revised 5-point MACE (rMACE-5: rMACE-3, coronary revascularization, hospitalization for heart failure) compared to tirzepatide (PMID 41491349). However, a separate analysis in patients with cardiometabolic heart failure with preserved ejection fraction (HFpEF) found that while both semaglutide and tirzepatide initiators had substantially lower risk of a composite of hospitalization for heart failure or all-cause mortality compared with sitagliptin, tirzepatide had no meaningfully lowered risk compared with semaglutide (HR, 0.86 [95% CI, 0.70-1.06]) (PMID 40886075). Current abstracts do not provide direct human evidence on retatrutide's cardiovascular outcomes, though its Phase 3 program includes a trial for weight management in a population with CVD (TRIUMPH-3) (PMID 41090431).

Head-to-head comparisons and network meta-analyses provide insights into the relative weight loss efficacy of these agents. In adults with obesity but without type 2 diabetes, a phase 3b, open-label, controlled trial directly compared tirzepatide and semaglutide (PMID 40353578). At 72 weeks, the least-squares mean percent change in weight was -20.2% with tirzepatide and -13.7% with semaglutide (P<0.001), indicating tirzepatide's superiority in weight reduction in this human population (PMID 40353578). Participants receiving tirzepatide were also more likely to achieve weight reductions of at least 10%, 15%, 20%, and 25% (PMID 40353578). This is consistent with a systematic review and meta-analysis of direct comparative studies in type 2 diabetes patients, which found that tirzepatide demonstrated a higher impact on weight loss than semaglutide, with a mean difference of -4.84 kg favoring tirzepatide (PMID 40184508).

When retatrutide is included in comparisons, a Bayesian network meta-analysis (NMA) evaluated the efficacy and safety of GLP-1 receptor agonists, dual agonists (GLP-1RAs/GIP or GCGR), and retatrutide (GLP-1/GIP/glucagon) for weight loss in adults with overweight or obesity (PMID 40685589). This human NMA of 19 RCTs including 29,506 adults found that retatrutide and dual agonists (like tirzepatide) achieved equivalent mean weight loss of -11.0 kg, surpassing GLP-1RAs (like semaglutide) which achieved -9.0 kg (PMID 40685589). However, retatrutide excelled at achieving ≥15% weight loss (OR 54.6), with dual agonists and GLP-1RAs following (OR 16.4 and 9.0, respectively) (PMID 40685589). This suggests a potentially greater magnitude of weight loss with retatrutide, particularly for higher thresholds of reduction, in human subjects.

An observational cohort study using electronic health record data also compared on-treatment weight loss between tirzepatide and semaglutide in adults with overweight or obesity (PMID 38976257). Among 18,386 propensity score-matched patients, those receiving tirzepatide were significantly more likely to achieve weight loss thresholds of ≥5%, ≥10%, and ≥15% (HRs of 1.76, 2.54, and 3.24, respectively) (PMID 38976257). On-treatment changes in weight were larger for patients receiving tirzepatide (PMID 38976257). These real-world human data further support tirzepatide's superior weight loss efficacy over semaglutide. While direct head-to-head human comparisons of retatrutide against tirzepatide and semaglutide are still emerging, the NMA provides an indirect comparison suggesting retatrutide's potent effect on weight loss (PMID 40685589).

Across all three agents, gastrointestinal adverse events (AEs) are commonly reported and are generally mild to moderate in severity (PMID 37366315, PMID 34170647, PMID 38388874, PMID 40353578, PMID 39318607). For retatrutide, in human phase 2 trials, the most common AEs were gastrointestinal, dose-related, mostly mild to moderate, and partially mitigated with initial dose escalation strategies (PMID 37366315). A systematic review and meta-analysis on retatrutide similarly noted an increase in non-severe gastrointestinal and hypersensitivity adverse events compared to placebo (PMID 39318607). Another systematic review and meta-analysis observed no significant difference in adverse events between retatrutide and placebo groups overall, but specific gastrointestinal issues like nausea, diarrhea, and vomiting were common (PMID 40291085).

Tirzepatide and semaglutide also share a similar safety profile, with gastrointestinal events being prominent. In a phase 3 human trial comparing tirzepatide and semaglutide in type 2 diabetes, the most common AEs were gastrointestinal, including nausea (17-22% for tirzepatide, 18% for semaglutide), diarrhea (13-16% for tirzepatide, 12% for semaglutide), and vomiting (6-10% for tirzepatide, 8% for semaglutide) (PMID 34170647). These events were primarily mild to moderate (PMID 34170647). A review of tirzepatide for type 2 diabetes states it was generally well tolerated, with a safety profile consistent with GLP-1 RAs, and a low risk of clinically significant or severe hypoglycemia (PMID 38388874). The most common AEs were usually short-lived gastrointestinal-related events, such as nausea, diarrhea, and decreased appetite (PMID 38388874).

In the Bayesian NMA comparing GLP-1RAs, dual agonists, and retatrutide in human subjects, retatrutide was found to have the highest AE risk, while dual agonists (like tirzepatide) provided a favorable efficacy-safety balance (PMID 40685589). This suggests that while all agents have common gastrointestinal side effects, retatrutide's triple agonism might lead to a higher incidence or severity of certain AEs. However, the abstracts also highlight that these gastrointestinal AEs are often transient and manageable (PMID 37366315, PMID 38388874). Ongoing Phase 3 human trials for retatrutide aim to further evaluate its long-term safety and efficacy in diverse patient populations (PMID 40563436, PMID 39318607).

The therapeutic potential of these agents extends beyond core indications for weight loss and glycemic control, with ongoing investigations into new applications. For retatrutide, the TRIUMPH clinical development program is simultaneously evaluating its safety and efficacy for the treatment of obesity alongside two related complications: obstructive sleep apnea (OSA) and knee osteoarthritis (OA) (PMID 41090431). This 'basket trial' design allows for the independent analysis of retatrutide's effects across these adiposity-related disease states in human populations (PMID 41090431). Additionally, initial phase 2 human trials have demonstrated significant reductions in liver fat for participants with metabolic dysfunction-associated steatotic liver disease (PMID 38858523), suggesting a role in hepatic health.

GLP-1-based medicines, including semaglutide and tirzepatide, are being interrogated in ongoing trials for new indications beyond diabetes and obesity, such as metabolic liver disease, peripheral artery disease, Parkinson disease, and Alzheimer disease (PMID 38843460). Real-world evidence has also begun to shed light on their broader impact. A study involving human participants with obesity, who were current alcohol drinkers, observed a significantly lower self-reported intake of alcohol, fewer drinks per drinking episode, reduced binge drinking odds, and lower Alcohol Use Disorders Identification Test (AUDIT) scores in individuals taking semaglutide or tirzepatide compared to their pre-medication state and a control group (PMID 38017205). This suggests a potential efficacy for treatment in Alcohol Use Disorder comorbid with obesity (PMID 38017205).

Furthermore, real-world data are being used to assess cardiovascular outcomes. In an insured US population of patients with overweight/obesity and established atherosclerotic cardiovascular disease (ASCVD) but without diabetes, semaglutide was associated with significantly greater reductions in the risk of major adverse cardiovascular events (rMACE-3 and rMACE-5) compared to tirzepatide (PMID 41491349). This observational human study included 10,625 patients in each matched cohort (PMID 41491349). Another human study on patients with cardiometabolic HFpEF indicated that both semaglutide and tirzepatide substantially lowered the risk of hospitalization for heart failure or all-cause mortality compared with sitagliptin (PMID 40886075). These real-world analyses highlight the expanding understanding of these medications' effects in clinical practice, beyond controlled trial settings, although long-term follow-up and further randomized controlled trials are often warranted to confirm such observations.

Despite the significant advancements demonstrated by retatrutide, tirzepatide, and semaglutide, several open questions remain, particularly concerning long-term outcomes and broader clinical applications. For retatrutide, while Phase 2 human trials have shown substantial weight loss and improvements in metabolic markers, the 'quality of weight loss beyond BMI reduction' warrants further investigation (PMID 40563436). The ongoing Phase 3 TRIUMPH trials are designed to address long-term safety and efficacy in diverse patient populations, including those with obstructive sleep apnea, knee osteoarthritis, and cardiovascular disease (PMID 41090431, PMID 40563436). The comprehensive data from these large-scale human studies will be crucial for a more complete understanding of retatrutide's clinical profile.

For tirzepatide and semaglutide, while their efficacy in weight loss and glycemic control in humans is well-established, mechanistic differences warrant further exploration. For example, a secondary analysis comparing tirzepatide, semaglutide, and placebo in type 2 diabetes patients noted that while both tirzepatide and semaglutide significantly reduced appetite, differences in energy intake during an ad libitum lunch were not sufficient to explain the observed weight outcomes (PMID 36857477). This human study suggested that further evaluation is needed to assess mechanistic differences related to 24-hour energy intake, substrate utilization, and energy expenditure (PMID 36857477). Additionally, while real-world data offer valuable insights into comparative cardiovascular outcomes (PMID 41491349), the need for confirmatory head-to-head randomized controlled trials to better elucidate weight loss effects and safety profiles for tirzepatide versus semaglutide is still emphasized (PMID 40184508).

Finally, the expanding landscape of GLP-1-based medicines, including multi-agonists like retatrutide, points towards a future of personalized medicine (PMID 38843460). Rapid progress in their development and anticipated differentiation of newer agents in subsets of metabolic disorders will provide greater opportunities for tailored treatment approaches (PMID 38843460). Factors such as cost and specific patient characteristics (e.g., presence of type 2 diabetes, sex, BMI) are recognized as important considerations for personalized treatment selection (PMID 40563436, PMID 40685589). As new data emerge from ongoing Phase 3 human trials, a clearer picture of the optimal use cases for each of these powerful medications will undoubtedly form, guiding clinical decisions in the management of obesity, diabetes, and related complications.

• Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. — The New England journal of medicine (2023). PMID 37366315
• Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. — Nature medicine (2024). PMID 38858523
• Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. — Diabetes, obesity & metabolism (2026). PMID 41090431
• Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. — Lancet (London, England) (2023). PMID 37385280
• Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. — The lancet. Diabetes & endocrinology (2025). PMID 40609566
• Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. — Proceedings (Baylor University. Medical Center) (2025). PMID 40291085
• Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity. — Diabetes care (2024). PMID 38843460
• Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials. — Metabolism open (2024). PMID 39318607
• Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA. — Obesity (Silver Spring, Md.) (2025). PMID 40685589
• Retatrutide-A Game Changer in Obesity Pharmacotherapy. — Biomolecules (2025). PMID 40563436
• Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. — The New England journal of medicine (2021). PMID 34170647
• Tirzepatide: A Review in Type 2 Diabetes. — Drugs (2024). PMID 38388874
• Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world (STEER). — Diabetes, obesity & metabolism (2026). PMID 41491349
• Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes. — Diabetes care (2023). PMID 36857477
• Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. — JAMA internal medicine (2024). PMID 38976257
• Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction. — JAMA (2025). PMID 40886075
• Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity. — Scientific reports (2023). PMID 38017205
• Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. — The New England journal of medicine (2025). PMID 40353578
• Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Direct Comparative Studies. — Endocrinology, diabetes & metabolism (2025). PMID 40184508

Semaglutide, tirzepatide and retatrutide are supplied strictly for in-vitro and preclinical research use. They are not medicines, are not approved for human consumption in Spain, the United Kingdom, the European Union or the United States, and are not dispensed against a prescription. The research-use declaration ships with every package alongside the independent third-party COA.

Comparison pages on Peptide Intel Hub exist for laboratory-research reference. Nothing on this page constitutes a recommendation for human use of any of the three compounds.